Green Synthesis and Biomedical Applications of ZnO Nanoparticles: Role of PEGylated-ZnO Nanoparticles as Doxorubicin Drug Carrier against MDA-MB-231(TNBC) Cells Line

• Published in: Crystals (Basel) 2021-04, Vol.11 (4), p.344
• Main Authors: Batool, Madiha, Khurshid, Shazia, Daoush, Walid M., Siddique, Sabir Ali, Nadeem, Tariq
• Format: Article
• Language: English
• Subjects: Ablation; Acids; anticancer activity; Anticancer properties; Apoptosis; Atomic properties; Biodistribution; Biomedical materials; Breast cancer; Cancer therapies; Cell cycle; chemotherapeutic drugs; Chemotherapy; Cytotoxicity; Doxorubicin; Drug carriers; Drug delivery systems; Drugs; Efficiency; Electron microscopy; Energy dispersive X ray analysis; Fourier transforms; green synthesis; Infrared analysis; Infrared spectrophotometers; Infrared spectroscopy; Metabolism; Metal oxides; Metastasis; Nanoparticles; Polyethylene glycol; Signal transduction; Spectrophotometry; Synthesis; Tumors; X ray analysis; X-ray diffraction; Zinc oxide; Zinc oxides; ZnO nanoparticles
• ISSN: 2073-4352; 2073-4352
• DOI: 10.3390/cryst11040344

The present study aimed to develop the synthesis of zinc oxide nanoparticles (ZnO-NPs) using the green method, with Aloe barbadensis leaf extract as a stabilizing and capping agent. In vitro antitumor cytotoxic activity, as well as the surface-functionalization of ZnO-NPs and their drug loading capacity against doxorubicin (DOX) and gemcitabine (GEM) drugs, were also studied. Morphological and structural properties of the produced ZnO-NPs were characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersion X-ray diffraction (EDX), UV-Vis spectrophotometry, Fourier-transform infrared analysis (FTIR), and X-ray diffraction (XRD). The prepared ZnO-NPs had a hexagonal shape and average particle size of 20–40 nm, with an absorption peak at 325 nm. The weight and atomic percentages of zinc (50.58% and 28.13%) and oxygen (26.71% and 60.71%) were also determined by EDAX (energy dispersive x-ray analysis) compositional analysis. The appearance of the FTIR peak at 3420 m–1 confirmed the synthesis of ZnO-NPs. The drug loading efficiency (LE) and loading capacity (LC) of unstabilized and PEGylated ZnO-NPs were determined by doxorubicin (DOX) and gemcitabine (GEM) drugs. DOX had superior LE 65% (650 mg/g) and higher LC 32% (320 mg/g) than GEM LE 30.5% (30 mg/g) and LC 16.25% (162 mg/g) on ZnO-NPs. Similar observation was observed in the case of PEG-ZnO-NPs, where DOX had enhanced LE 68% (680 mg/g) and LC 35% (350) mg/g in contrast to GEM, which had LE and LC values of 35% (350 mg/g) and 19% (190 mg/g), respectively. Therefore, DOX was chosen to encapsulate nanoparticles, along with the untreated nanoparticles, to check their in vitro antiproliferative potential against the triple-negative breast cancer (TNBC) cell line (MDA-MB-231) through the MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide) assay. This drug delivery strategy implies that the PEGylated biogenically synthesized ZnO-NPs occupy an important position in chemotherapeutic drug loading efficiency and can improve the therapeutic techniques of triple breast cancer.